Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/39509
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorOrtiz Gómez, León Darío-
dc.contributor.authorSyro Moreno, Luis Vicente-
dc.contributor.authorErsen, Ayca-
dc.contributor.authorPenagos, Luis C.-
dc.contributor.authorUribe, Humberto-
dc.contributor.authorScheithauer, Bernd W.-
dc.contributor.authorRotondo, Fabio-
dc.contributor.authorHorvath, Eva-
dc.contributor.authorKovacs, Kalman-
dc.date.accessioned2024-05-31T22:41:01Z-
dc.date.available2024-05-31T22:41:01Z-
dc.date.issued2014-
dc.identifier.issn0317-1671-
dc.identifier.urihttps://hdl.handle.net/10495/39509-
dc.description.abstractABSTRACT: Endocrinologically active pituitary adenomas are treated either with surgery, radiotherapy or various drugs, including dopamine agonists, long-acting somatostatin analogs, growth hormone receptor antagonists, or corticosteroid secretion inhibitors. Fully 35% to 55% of pituitary adenomas invade adjacent structures. This figure is lower in gonadotroph adenomas, less than 5% compared to other adenoma types. Clinical management of invasive adenomas is challenging, and most of them tend to recur after surgery.spa
dc.format.extent3 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherCambridge University Pressspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleNon-uniform Response to Temozolomide Therapy in a Pituitary Gonadotroph Adenomaspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGenética, Regeneración y Cáncerspa
dc.identifier.doi10.1017/s0317167100018242-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn2057-0155-
oaire.citationtitleCanadian Journal of Neurological Sciencesspa
oaire.citationstartpage683spa
oaire.citationendpage685spa
oaire.citationvolume39spa
oaire.citationissue5spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.publisher.placeCambridge, Inglaterraspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTCASOspa
dc.type.localReporte de casospa
dc.subject.decsTemozolomida-
dc.subject.decsTemozolomide-
dc.subject.decsAdenoma-
dc.subject.decsAdenoma - cirugía-
dc.subject.decsAdenoma - tratamiento farmacológico-
dc.subject.decsAdenoma - radioterapia-
dc.description.researchgroupidCOL0006769spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000077204-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000236-
dc.relation.ispartofjournalabbrevCan. J. Neurol. Sci.spa
Aparece en las colecciones: Artículos de Revista en Ciencias Exactas y Naturales

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
SyroLuis_2014_Non-uniformResponse.pdfReporte de caso300.32 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons